SpringWorks Therapeutics (SWTX) Competitors $46.99 0.00 (0.00%) As of 07/1/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SWTX vs. ITCI, GMAB, MRNA, RDY, VTRS, QGEN, ASND, BBIO, VRNA, and BPMCShould you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. SpringWorks Therapeutics vs. Its Competitors Intra-Cellular Therapies Genmab A/S Moderna Dr. Reddy's Laboratories Viatris Qiagen Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines SpringWorks Therapeutics (NASDAQ:SWTX) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership. Does the media prefer SWTX or ITCI? In the previous week, SpringWorks Therapeutics had 2 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 3 mentions for SpringWorks Therapeutics and 1 mentions for Intra-Cellular Therapies. SpringWorks Therapeutics' average media sentiment score of 1.87 beat Intra-Cellular Therapies' score of 0.29 indicating that SpringWorks Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SpringWorks Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, SWTX or ITCI? SpringWorks Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Is SWTX or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to SpringWorks Therapeutics' net margin of -115.60%. Intra-Cellular Therapies' return on equity of -9.93% beat SpringWorks Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SpringWorks Therapeutics-115.60% -51.10% -43.80% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has better earnings and valuation, SWTX or ITCI? Intra-Cellular Therapies has higher revenue and earnings than SpringWorks Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpringWorks Therapeutics$191.59M18.48-$258.13M-$3.41-13.78Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Do institutionals and insiders have more ownership in SWTX or ITCI? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 7.8% of SpringWorks Therapeutics shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend SWTX or ITCI? SpringWorks Therapeutics presently has a consensus target price of $52.57, suggesting a potential upside of 11.88%. Intra-Cellular Therapies has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Given SpringWorks Therapeutics' higher probable upside, equities analysts clearly believe SpringWorks Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SpringWorks Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 SummaryIntra-Cellular Therapies beats SpringWorks Therapeutics on 11 of the 16 factors compared between the two stocks. Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SWTX vs. The Competition Export to ExcelMetricSpringWorks TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.54B$2.93B$5.52B$9.35BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-13.7820.5927.9519.83Price / Sales18.48289.89438.79106.18Price / CashN/A42.3835.5357.53Price / Book7.267.788.255.72Net Income-$258.13M-$55.11M$3.23B$257.51M7 Day PerformanceN/A1.31%-0.13%0.59%1 Month Performance0.28%11.91%7.21%10.74%1 Year Performance20.80%0.19%27.45%15.87% SpringWorks Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SWTXSpringWorks Therapeutics1.6096 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230News CoverageITCIIntra-Cellular Therapies0.9163 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9269 of 5 stars$21.40-2.1%$37.80+76.6%-19.0%$13.73B$3.12B12.162,682Analyst RevisionMRNAModerna4.2711 of 5 stars$33.64-1.9%$46.61+38.6%-74.4%$13.01B$3.14B-3.855,800Analyst RevisionRDYDr. Reddy's Laboratories2.77 of 5 stars$14.51-1.1%$16.95+16.8%-6.7%$12.11B$3.81B21.9827,811News CoverageVTRSViatris3.0728 of 5 stars$9.12-1.4%$10.40+14.0%-20.2%$10.70B$14.33B-2.8832,000News CoveragePositive NewsQGENQiagen3.7165 of 5 stars$48.13-0.9%$49.40+2.6%+16.7%$10.70B$2.00B120.675,765ASNDAscendis Pharma A/S3.7228 of 5 stars$174.96-0.9%$223.07+27.5%+24.6%$10.70B$393.54M-27.861,017BBIOBridgeBio Pharma4.6348 of 5 stars$46.47+0.4%$60.21+29.6%+61.0%$8.82B$127.42M-13.16400Trending NewsAnalyst ForecastAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share2.29 of 5 stars$104.830.0%$107.45+2.5%+370.5%$8.50B$118.54M-52.4230Analyst ForecastHigh Trading VolumeBPMCBlueprint Medicines1.1191 of 5 stars$129.300.0%$128.25-0.8%+7.3%$8.35B$508.82M-52.35640Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Viatris Competitors Qiagen Competitors Ascendis Pharma A/S Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Blueprint Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SWTX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SWTX Stock Alerts